JP2020505317A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505317A5 JP2020505317A5 JP2019522742A JP2019522742A JP2020505317A5 JP 2020505317 A5 JP2020505317 A5 JP 2020505317A5 JP 2019522742 A JP2019522742 A JP 2019522742A JP 2019522742 A JP2019522742 A JP 2019522742A JP 2020505317 A5 JP2020505317 A5 JP 2020505317A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- nucleic acid
- acid molecule
- administering
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023016007A JP2023041950A (ja) | 2017-01-20 | 2023-02-06 | 臍帯血移植（ｕｃｂｔ）および増加したガラクトセレブロシダーゼの発現によるクラッベ病の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448433P | 2017-01-20 | 2017-01-20 | |
| US62/448,433 | 2017-01-20 | ||
| PCT/US2018/014370 WO2018136710A1 (en) | 2017-01-20 | 2018-01-19 | Treatment of krabbe disease with umbilical cord blood transplantion (ucbt) and increased galactocerebrosidase (galc) expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023016007A Division JP2023041950A (ja) | 2017-01-20 | 2023-02-06 | 臍帯血移植（ｕｃｂｔ）および増加したガラクトセレブロシダーゼの発現によるクラッベ病の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505317A JP2020505317A (ja) | 2020-02-20 |
| JP2020505317A5 true JP2020505317A5 (enExample) | 2021-02-25 |
Family
ID=62908818
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522742A Withdrawn JP2020505317A (ja) | 2017-01-20 | 2018-01-19 | 臍帯血移植（ｕｃｂｔ）および増加したガラクトセレブロシダーゼの発現によるクラッベ病の処置 |
| JP2023016007A Pending JP2023041950A (ja) | 2017-01-20 | 2023-02-06 | 臍帯血移植（ｕｃｂｔ）および増加したガラクトセレブロシダーゼの発現によるクラッベ病の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023016007A Pending JP2023041950A (ja) | 2017-01-20 | 2023-02-06 | 臍帯血移植（ｕｃｂｔ）および増加したガラクトセレブロシダーゼの発現によるクラッベ病の処置 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12599636B2 (enExample) |
| EP (1) | EP3571298B1 (enExample) |
| JP (2) | JP2020505317A (enExample) |
| KR (1) | KR20190106990A (enExample) |
| CN (2) | CN118078860A (enExample) |
| AU (1) | AU2018210326B9 (enExample) |
| CA (1) | CA3042467A1 (enExample) |
| IL (1) | IL266287A (enExample) |
| WO (1) | WO2018136710A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3884057A4 (en) | 2018-12-21 | 2022-09-07 | The University of North Carolina at Chapel Hill | OPTIMIZED GALC GENES AND EXPRESSION CASSETTE AND THEIR USE |
| EP3931337A1 (en) * | 2019-02-26 | 2022-01-05 | The Trustees of The University of Pennsylvania | Compositions useful in treatment of krabbe disease |
| EA202192328A1 (ru) * | 2019-03-22 | 2022-02-21 | Раш Юниверсити Медикал Сентер | Комбинация назальной доставки генов и пероральной доставки коричной кислоты, олеамида или гемфиброзила для лечения лизосомных болезней накопления |
| AU2021271635A1 (en) * | 2020-05-12 | 2023-01-05 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of krabbe disease |
| WO2021262498A1 (en) * | 2020-06-26 | 2021-12-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and materials for treating non-malignant disorders or diseases with cord blood |
| WO2022170098A2 (en) * | 2021-02-05 | 2022-08-11 | Sigilon Therapeutics, Inc. | Compositions, devices and methods for treating mps vi disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US6730297B1 (en) | 1999-05-28 | 2004-05-04 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| WO2004042033A2 (en) | 2002-11-01 | 2004-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Circulating stem cells and uses related thereto |
| US9986722B2 (en) * | 2012-08-07 | 2018-06-05 | Chiesi Farmaceutici S.P.A. | Animal model of Krabbe's disease |
-
2018
- 2018-01-19 JP JP2019522742A patent/JP2020505317A/ja not_active Withdrawn
- 2018-01-19 EP EP18741529.4A patent/EP3571298B1/en active Active
- 2018-01-19 KR KR1020197012608A patent/KR20190106990A/ko not_active Ceased
- 2018-01-19 AU AU2018210326A patent/AU2018210326B9/en active Active
- 2018-01-19 CN CN202410102735.9A patent/CN118078860A/zh active Pending
- 2018-01-19 WO PCT/US2018/014370 patent/WO2018136710A1/en not_active Ceased
- 2018-01-19 CN CN201880004477.3A patent/CN110168085A/zh active Pending
- 2018-01-19 US US16/349,514 patent/US12599636B2/en active Active
- 2018-01-19 CA CA3042467A patent/CA3042467A1/en active Pending
-
2019
- 2019-04-28 IL IL266287A patent/IL266287A/en unknown
-
2023
- 2023-02-06 JP JP2023016007A patent/JP2023041950A/ja active Pending
-
2026
- 2026-03-20 US US19/573,927 patent/US20260224639A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7374119B2 (ja) | 減少した肝臓向性を有するＡＡＶ９とＡＡＶｒｈ７４とのハイブリッド組換えアデノ随伴ウイルス血清型 | |
| Khandpur et al. | Stem cell therapy in dermatology | |
| Jiang et al. | Modifying strategies for SDF-1/CXCR4 interaction during mesenchymal stem cell transplantation | |
| JP2020203926A5 (enExample) | ||
| JP2023504314A5 (enExample) | ||
| Locatelli et al. | Autologous gene therapy for hemoglobinopathies: From bench to patient’s bedside | |
| JP2016538885A5 (enExample) | ||
| JP2018510881A5 (enExample) | ||
| WO2023060269A4 (en) | Recombinant adeno-associated viruses for targeted delivery | |
| JP2017529326A5 (enExample) | ||
| US20240158528A1 (en) | Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies | |
| JP2023535121A5 (enExample) | ||
| Zoellner et al. | Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma | |
| JP2022519196A5 (enExample) | ||
| Ballen | Targeting the stem cell niche: squeezing blood from bones | |
| Batzios et al. | Developing treatment options for metachromatic leukodystrophy | |
| Jones et al. | The next horizon now that everyone has a donor: Precision allogeneic transplantation | |
| JP2022530168A5 (enExample) | ||
| Pollock et al. | Gene-addition/editing therapy in sickle cell disease | |
| De Astis et al. | Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia | |
| JP2008502323A5 (enExample) | ||
| Pulsipher et al. | Successful treatment of JMML relapsed after unrelated allogeneic transplant with cytoreduction followed by DLI and interferon-alpha: evidence for a graft-versus-leukemia effect in non-monosomy-7 JMML | |
| Yanagisawa et al. | Low toxicity of a conditioning with 8‐Gy total body irradiation, fludarabine and cyclophosphamide as preparative regimen for allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies | |
| Al-Anazi et al. | An update on hematopoietic stem cell transplantation in patients with multiple myeloma | |
| JP2018512844A5 (enExample) |